news
Pfizer and Synthon enter commercialisation agreement
4 August 2015 | By Victoria White
Pfizer and Synthon have entered into an agreement whereby Pfizer has acquired the exclusive commercialisation rights in the US to glatiramer acetate...
List view / Grid view
Multiple sclerosis
news
Ocrelizumab significantly reduced both relapses and disability progression in two Phase III studies in MS
30 June 2015 | By Victoria White
Roche has announced positive results from two studies evaluating ocrelizumab compared with interferon beta-1a in people with relapsing multiple sclerosis...
news
First patient enrolled in Phase II study evaluating laquinimod for primary progressive MS
24 April 2015 | By Victoria White
The first patient has been enrolled in a Phase II study evaluating laquinimod, an investigational, oral, immune modulator, for the treatment of PPMS...
news
Phase III study of MD1003 in patients with progressive multiple sclerosis meets primary endpoint
17 April 2015 | By Victoria White
The primary endpoint has been met in the pivotal clinical trial MS-SPI of MD1003 in the treatment of progressive multiple sclerosis...
news
Actelion initiates Phase III development of ponesimod for patients with relapsing MS
16 April 2015 | By Victoria White
Actelion has initiated Phase III development with ponesimod, its lead compound, in patients suffering from relapsing multiple sclerosis (MS)...
news
EMA validates Marketing Authorisation Application for Zinbryta for treatment of MS
31 March 2015 | By Victoria White
Biogen and AbbVie have announced that the EMA has validated the companies’ MAA for Zinbryta for the treatment of relapsing forms of MS in the EU...
news
GeNeuro successful Phase 2a clinical study reinforces novel approach to treat multiple sclerosis
3 September 2014 | By GeNeuro
GeNeuro SA, a pioneer of new therapies for neurology disorders, announced positive results from a one-year, open-label extension of a Phase IIa study...
news
Gilenya® data at ACTRIMS-ECTRIMS to show Novartis is redefining MS treatment goals for patients
3 September 2014 | By Novartis
Novartis announced that new analyses to be presented at the Joint ACTRIMS-ECTRIMS Meeting in Boston, USA from September 10-13, 2014...
news
Biogen Idec’s PLEGRIDY™(Peginterferon Beta-1a) approved in the US for the treatment of multiple sclerosis
18 August 2014 | By Biogen Idec
Biogen Idec announced that the U.S. Food and Drug Administration has approved PLEGRIDYTM (peginterferon beta-1a), a new treatment for people with relapsing forms of multiple sclerosis...
news
Biogen Idec and Yahoo Health spotlight visionaries whose work benefits people with multiple sclerosis (MS)
16 July 2014 | By Biogen Idec
Biogen Idec announced a new program with Yahoo Health to raise awareness of innovative efforts to help people with multiple sclerosis across the country...
news
Genzyme’s Lemtrada resubmission accepted for review by FDA
30 May 2014 | By Sanofi
Sanofi and its subsidiary Genzyme announced that the U.S. Food and Drug Administration has accepted for review the company’s resubmission of its supplemental Biologics License Application (sBLA) seeking approval of Lemtrada...
news
Genzyme’s multiple sclerosis franchise featured at ECTRIMS
27 September 2013 | By Genzyme
18 platform and poster presentations provide deeper insight into the Clinical Development Programs for Aubagio® and Lemtrada™...
news
Teva presents new multiple sclerosis data 29th ECTRIMS Congress
27 September 2013 | By Teva Pharmaceutical Industries Ltd
Series of events throughout Congress to shed light on new data and evolving MS landscape...
news
Biogen Idec to present extensive new data from its robust multiple sclerosis portfolio at ECTRIMS
23 September 2013 | By Biogen Idec
More than 55 company-sponsored presentations underscore Biogen Idec’s commitment to treatment advances for people with MS...
news
European Commission approves Genzyme’s multiple sclerosis treatment Lemtrada™ (alemtuzumab)
17 September 2013 | By Genzyme
Follows recent European Commission approval of multiple sclerosis treatment Aubagio® (teriflunomide)...
